Identificador persistente para citar o vincular este elemento: https://accedacris.ulpgc.es/handle/10553/139932
Campo DC Valoridioma
dc.contributor.authorSalas-Salas, Barbara Gabrielaen_US
dc.contributor.authorFerrera Alayón, Lauraen_US
dc.contributor.authorCalleja-Fernandez, Aliciaen_US
dc.contributor.authorChicas-Sett, Rodolfoen_US
dc.contributor.authorNogues-Ramia, Evaen_US
dc.contributor.authorZafra-Martin, Juanen_US
dc.contributor.authorLloret Sáez-Bravo, Martaen_US
dc.date.accessioned2025-06-11T08:14:08Z-
dc.date.available2025-06-11T08:14:08Z-
dc.date.issued2024en_US
dc.identifier.issn2296-861Xen_US
dc.identifier.otherWoS-
dc.identifier.otherScopus-
dc.identifier.urihttps://accedacris.ulpgc.es/handle/10553/139932-
dc.description.abstractBackground: Patients with rectal cancer may develop gastrointestinal toxicity associated with chemo-radiotherapeutic treatment that conditions their clinical, functional, and nutritional evolution. The aim of the study was to evaluate the efficacy of nutritional supplementation with a glutamine-enriched peptide diet (PD) compared to exclusive dietary advice (DA) on gastrointestinal toxicity, interruption of oncologic treatment, and nutritional evolution in patients with rectal cancer undergoing neoadjuvant treatment.Methods Prospective cohort study with two groups. Patients with rectal cancer in treatment with neoadjuvant chemo-radiotherapy were recruited. One group of patients received nutritional supplementation with PD, and another group received DA exclusively, from the beginning of radiotherapy until the time of surgery. Intestinal toxicity was evaluated with the CTCAE 5.0 scale, functionality with the ECOG scale and nutritional status with GLIM criteria.Results Fifty-four patients were initially selected, although 51 were finally enrolled: 25 in the PD group and 26 in the DA group. There was a reduction in the risk of diarrhea in the PD group midway through radiotherapy treatment [RR of 0.218 (95% CI = 0.052-0.923)] and at the end of treatment [RR of 0.103 (95% CI = 0.020-0.537)], as well as a reduction in the risk of developing mucositis at the end of treatment [RR of 0.405 (95% CI = 0.280-0.584)]. The use of a PD also decreased treatment interruptions with radiotherapy in stage III patients (0 vs. 15.8%, p = 0.049) and in malnourished patients (0 vs. 18.2%, p = 0.040).Conclusion The glutamine-enriched peptide diet had a protective effect on the development of diarrhea and mucositis associated with chemo-radiotherapeutic treatment in patients with colorectal cancer under neoadjuvant treatment, as well as the interruption of radiotherapeutic treatment.en_US
dc.languageengen_US
dc.relation.ispartofFrontiers In Nutritionen_US
dc.sourceFrontiers In Nutrition [ISSN 2296-861X], v. 11, (Diciembre 2024)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320101 Oncologíaen_US
dc.subject3208 Farmacodinámicaen_US
dc.subject.otherInduced Oral Mucositisen_US
dc.subject.otherElemental Dieten_US
dc.subject.otherRadiation Enteritisen_US
dc.subject.otherColorectal-Canceren_US
dc.subject.otherChemotherapyen_US
dc.subject.otherNutritionen_US
dc.subject.otherEfficacyen_US
dc.subject.otherAciden_US
dc.subject.otherChemoradiotherapyen_US
dc.subject.otherMetaanalysisen_US
dc.subject.otherPeptide Dieten_US
dc.subject.otherOral Nutritional Supplementen_US
dc.subject.otherRadiotherapyen_US
dc.subject.otherRectal Canceren_US
dc.subject.otherGlutamineen_US
dc.titleImpact of a glutamine-enriched peptide formula on gastrointestinal toxicity and on the interruption of oncologic treatment in patients with adenocarcinoma of the rectumen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fnut.2024.1414367en_US
dc.identifier.scopus85214024667-
dc.identifier.isi001388790000001-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.authorscopusid57209142019-
dc.contributor.authorscopusid57209144026-
dc.contributor.authorscopusid35110995800-
dc.contributor.authorscopusid57190872784-
dc.contributor.authorscopusid57217064444-
dc.contributor.authorscopusid57208737651-
dc.contributor.authorscopusid7003855087-
dc.identifier.eissn2296-861X-
dc.relation.volume11en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid67080984-
dc.contributor.daisngid20889526-
dc.contributor.daisngid50140879-
dc.contributor.daisngid959685-
dc.contributor.daisngid26358519-
dc.contributor.daisngid2490050-
dc.contributor.daisngid10747011-
dc.description.numberofpages10en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Salas-Salas, BG-
dc.contributor.wosstandardWOS:Ferrera-Alayón, L-
dc.contributor.wosstandardWOS:Calleja-Fernández, A-
dc.contributor.wosstandardWOS:Chicas-Sett, R-
dc.contributor.wosstandardWOS:Nogués-Ramia, E-
dc.contributor.wosstandardWOS:Zafra-Martín, J-
dc.contributor.wosstandardWOS:Lloret, M-
dc.date.coverdateDiciembre 2024en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,828
dc.description.jcr4,0
dc.description.sjrqQ1
dc.description.jcrqQ2
dc.description.esciESCI
dc.description.miaricds8,3
item.grantfulltextopen-
item.fulltextCon texto completo-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.fullNameFerrera Alayón, Laura-
crisitem.author.fullNameLloret Sáez-Bravo, Marta-
Colección:Artículos
Adobe PDF (711,87 kB)
Vista resumida

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.